Biogen’s monoclonal antibody felzartamab wins first global approval in Chinanews2026-08-14T17:11:14+00:00August 14th, 2026|Endpoints News|
Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional datanews2026-08-14T15:33:45+00:00August 14th, 2026|Endpoints News|
Redx tries again at reverse merger, with Skye this time, as route gains steamnews2026-08-14T15:30:52+00:00August 14th, 2026|Endpoints News|
Abcuro gets $66M for Phase 3 in muscle-weakening conditionnews2026-08-14T15:28:46+00:00August 14th, 2026|Endpoints News|
ICER says AstraZeneca’s new blood pressure med isn’t cost-effectivenews2026-08-14T15:15:46+00:00August 14th, 2026|Endpoints News|
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlontanews2026-08-14T14:10:55+00:00August 14th, 2026|Endpoints News|
Bicara shakes up leadership ahead of CEO departure; J&J’s John Reed joins Madrigal’s boardnews2026-08-14T11:00:58+00:00August 14th, 2026|Endpoints News|
FDA approves Bristol Myers’ multiple myeloma successornews2026-08-13T21:19:05+00:00August 13th, 2026|Endpoints News|
‘Incorrect and misleading’ data prompted decision to pull Tavneos in Europenews2026-08-13T18:39:13+00:00August 13th, 2026|Endpoints News|
Ovid and Takeda’s epilepsy drug gets new life at Perceptive-backed NewConews2026-08-13T18:31:07+00:00August 13th, 2026|Endpoints News|
